“We estimate that an average top-20 pharma company that adopted advanced RWE analytics across its whole value chain for in-market and pipeline products could unlock more than $300 million a year over the next three to five years.”
McKinsey & Company “Creating value from next-generation real-world evidence” July 23, 2020
Why work with Verantos?
- Many critical variables are rarely⎯or never⎯present in structured data. Our advanced, AI-based approach to RWD produces clinically rich data, which includes high-reliability disease subtypes, signs and symptoms, findings, and inferred variables.
- Company data sets reflect the highest data quality standard in the industry. To be high-reliability, accuracy, completeness, and traceability must all be measured and exceed a high threshold.
- The company has direct relationships with US academic medical centers and community health systems throughout the United States. The breadth and geographic distribution of the network provides generalizability and external validity.
- No other company provides RWD of sufficient quality to generate high-validity RWE at scale. Manual curation, as is common in oncology and rare disease, does not scale to populations > 100 patients.
Our track record speaks for itself
- Verantos is a market leader in high-validity real-world evidence (RWE) and the only firm able to achieve high validity at scale.
- We are defining the field of high-validity RWE through Congressional testimony on the 21st Century Cures Initiative, selection as the FDA-demonstration project to enable regulatory guidance on data quality, and high-validity RWE publications with leading life sciences firms and health systems.
- Verantos is the only RWE firm to have its science peer-reviewed, validated, and funded by the NIH, NSF, and FDA.
- Our RWE and RWD products have been validated through commercial engagements with multiple top 10 life sciences firms, which are increasingly using Verantos as the high-validity RWE vendor of choice.